S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

$5.71
-0.11 (-1.89%)
(As of 02/23/2024 ET)
Today's Range
$5.61
$5.87
50-Day Range
$5.08
$7.65
52-Week Range
$4.82
$9.33
Volume
2.73 million shs
Average Volume
3.27 million shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.29

BioCryst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.7% Upside
$13.29 Price Target
Short Interest
Bearish
14.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.25mentions of BioCryst Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.95) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.91 out of 5 stars

Medical Sector

219th out of 940 stocks

Biological Products, Except Diagnostic Industry

32nd out of 158 stocks

BCRX stock logo

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Stock Price History

BCRX Stock News Headlines

SHOCKING Crypto Leak Reveal Crypto's Set To SURGE
A shocking leak has revealed tech giant Microsoft plans to add crypto support to future products. If the plans in these leaked documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, and MORE. The coupling of gaming and cryptocurrency could transform digital finance as we know it. We've gathered 27 experts to share their top picks and predictions for the 2024 crypto bull run.
BioCryst to Present at Upcoming Investor Conferences
BioCryst to Present at Upcoming Investor Conferences
BioCryst Launches ORLADEYO® (berotralstat) in Italy
BioCryst Launches ORLADEYO® (berotralstat) in Italy
Gold explodes past $2,000, here's what's next
After what feels like nearly a decade of disappointing returns, gold is entering a new bull market. You can get started today for just $5.
BCRX Mar 2024 3.000 call
BCRX Mar 2024 5.000 put
Biotech firm with Birmingham facility cuts R&D jobs
Durham drugmaker BioCryst cuts dozens of jobs
What's Going On With BioCryst Pharmaceuticals Stock?
RBC Capital Keeps Their Buy Rating on BioCryst (BCRX)
See More Headlines
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
2/23/2024
Next Earnings (Confirmed)
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCRX
CUSIP
09058V10
Employees
531
Year Founded
1986

Price Target and Rating

Average Stock Price Target
$13.29
High Stock Price Target
$30.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+132.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-247,120,000.00
Pretax Margin
-73.86%

Debt

Sales & Book Value

Annual Sales
$270.83 million
Book Value
($1.58) per share

Miscellaneous

Free Float
195,797,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
1.91

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














BCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings
or view top-rated stocks.

What is BioCryst Pharmaceuticals' stock price target for 2024?

7 Wall Street analysts have issued 12 month price targets for BioCryst Pharmaceuticals' shares. Their BCRX share price targets range from $10.00 to $30.00. On average, they expect the company's share price to reach $13.29 in the next twelve months. This suggests a possible upside of 132.7% from the stock's current price.
View analysts price targets for BCRX
or view top-rated stocks among Wall Street analysts.

How have BCRX shares performed in 2024?

BioCryst Pharmaceuticals' stock was trading at $5.99 at the start of the year. Since then, BCRX stock has decreased by 4.7% and is now trading at $5.71.
View the best growth stocks for 2024 here
.

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our BCRX earnings forecast
.

How can I listen to BioCryst Pharmaceuticals' earnings call?

BioCryst Pharmaceuticals will be holding an earnings conference call on Monday, February 26th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. The biotechnology company earned $81.01 million during the quarter, compared to the consensus estimate of $81.42 million. BioCryst Pharmaceuticals's revenue was up 24.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.32) earnings per share.

What ETFs hold BioCryst Pharmaceuticals' stock?
What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?
Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.67%), Avoro Capital Advisors LLC (6.37%), Braidwell LP (2.79%), Kynam Capital Management LP (2.25%), Nuveen Asset Management LLC (1.69%) and Fisher Asset Management LLC (1.41%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends
.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCRX) was last updated on 2/23/2024 by MarketBeat.com Staff

From Our Partners